Title | Major histocompatibility complex-restricted recognition of autologous chronic lymphocytic leukemia by tumor-specific T cells. |
Publication Type | Journal Article |
Year of Publication | 1993 |
Authors | Sherman W, Liu Z, Inghirami G, Reed EF, Harris PE, Suciu-Foca NM |
Journal | Immunol Res |
Volume | 12 |
Issue | 4 |
Pagination | 338-48 |
Date Published | 1993 |
ISSN | 0257-277X |
Keywords | Amino Acid Sequence, Antibodies, Monoclonal, Antigens, Neoplasm, B-Lymphocytes, Base Sequence, Blotting, Southern, CD4-Positive T-Lymphocytes, Cell Line, Transformed, Cytotoxicity Tests, Immunologic, Genes, Immunoglobulin, HLA Antigens, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphocyte Activation, Male, Molecular Sequence Data, T-Lymphocytes |
Abstract | From the peripheral blood of a patient with chronic lymphocytic leukemia (CLL) we generated a T-cell line and clones which recognized autologous CLL. The line comprised T-cell clones which responded to the CLL as well as to autologous Epstein-Barr virus (EBV)-transformed B cells in an HLA-DR-restricted fashion. In addition, the line comprised clones which were CLL-specific and showed no reactivity against EBV-transformed B cells and against autologous peripheral blood mononuclear cells obtained during remission. The proliferative response of the CLL-specific T-cell clone was inhibited by monoclonal antibodies to HLA-DR11, the major histocompatibility complex (MHC)-restrictive element. These results indicate that the MHC class-II molecule of CLL binds a tumor-specific peptide which is recognized by autologous T cells in an MHC class-II-restricted fashion. Such a peptide may serve as a target for immunotherapy. |
DOI | 10.1007/BF02935507 |
Alternate Journal | Immunol Res |
PubMed ID | 7908684 |
Grant List | R01-A125210-06 / / PHS HHS / United States |
Related Faculty:
Giorgio Inghirami, M.D.